Halloween has come and gone in the US, and Americans are now gearing up for Thanksgiving and Christmas. But before the holiday season could get underway, the country went through a major political event with far-reaching implications: the midterm elections.As…
Ferring Pharmaceuticals and Boehringer Ingelheim Japan on July 15 launched their newly listed therapies Adstiladrin (nadofaragene firadenovec) and Jascayd (nerandomilast), while Taiho Pharmaceutical said the PI3Kα inhibitor Haizexin (risovalisib) will go on sale on July 28. Adstiladrin, a non-replicating gene…
To read the full story
Related Article
BUSINESS
- Nipro Eyes 50-60 Stemirac Treatment Sites across Japan after Full Nod
November 20, 2026
- AstraZeneca’s Etcamah to Hit Japan Market on Nov. 27
November 20, 2026
- Japan Drug Makers’ Sales Seen Dipping in FY2026 on Co-Marketing Exits
November 20, 2026
- J&J’s Icotyde Could Broaden Psoriasis Treatment Options: Expert
November 20, 2026
- Nippon Kayaku to Acquire AstraZeneca’s Zoladex on Dec. 16
November 20, 2026





